Literature DB >> 25393701

A clinical classification of the acute respiratory distress syndrome for predicting outcome and guiding medical therapy*.

Jesús Villar1, Rosa L Fernández, Alfonso Ambrós, Laura Parra, Jesús Blanco, Ana M Domínguez-Berrot, José M Gutiérrez, Lluís Blanch, José M Añón, Carmen Martín, Francisca Prieto, Javier Collado, Lina Pérez-Méndez, Robert M Kacmarek.   

Abstract

OBJECTIVE: Current in-hospital mortality of the acute respiratory distress syndrome (ARDS) is above 40%. ARDS outcome depends on the lung injury severity within the first 24 hours of ARDS onset. We investigated whether two widely accepted cutoff values of PaO2/FIO2 and positive end-expiratory pressure (PEEP) would identify subsets of patients with ARDS for predicting outcome and guiding therapy.
DESIGN: A 16-month (September 2008 to January 2010) prospective, multicenter, observational study.
SETTING: Seventeen multidisciplinary ICUs in Spain. PATIENTS: We studied 300 consecutive, mechanically ventilated patients meeting American-European Consensus Conference criteria for ARDS (PaO2/FIO2 ≤ 200 mm Hg) on PEEP greater than or equal to 5 cm H2O, and followed up until hospital discharge.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Based on threshold values for PaO2/FIO2 (150 mm Hg) and PEEP (10 cm H2O) at ARDS onset and at 24 hours, we assigned patients to four categories: group I (PaO2/FIO2 ≥ 150 on PEEP < 10), group II (PaO2/FIO2 ≥ 150 on PEEP ≥ 10), group III (PaO2/FIO2 < 150 on PEEP < 10), and group IV (PaO2/FIO2 < 150 on PEEP ≥ 10). The primary outcome was all-cause in-hospital mortality. Overall hospital mortality was 46.3%. Although at study entry, patients with PaO2/FIO2 less than 150 had a higher mortality than patients with a PaO2/FIO2 greater than or equal to 150 (p = 0.044), there was minimal variability in mortality among the four groups (p = 0.186). However, classification of patients in each group changed markedly after 24 hours of usual care. Group categorization at 24 hours provided a strong association with in-hospital mortality (p < 0.00001): group I had the lowest mortality (23.1%), whereas group IV had the highest mortality (60.3%).
CONCLUSIONS: The degree of lung dysfunction established by a PaO2/FIO2 of 150 mm Hg and a PEEP of 10 cm H2O demonstrated that ARDS is not a homogeneous disorder. Rather, it is a series of four subsets that should be considered for enrollment in clinical trials and for guiding therapy. A major contribution of our study is the distinction between survival after 24 hours of care versus survival at the time of ARDS onset.

Entities:  

Mesh:

Year:  2015        PMID: 25393701     DOI: 10.1097/CCM.0000000000000703

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  26 in total

1.  External validation confirms the legitimacy of a new clinical classification of ARDS for predicting outcome.

Authors:  Lieuwe D Bos; Olaf L Cremer; David S Y Ong; Eliana B Caser; Carmen S V Barbas; Jesus Villar; Robert M Kacmarek; Marcus J Schultz
Journal:  Intensive Care Med       Date:  2015-07-23       Impact factor: 17.440

2.  Sleep quality in survivors of critical illness: practical shortcomings unresolved.

Authors:  Mohamad F El-Khatib; Antonio M Esquinas
Journal:  Sleep Breath       Date:  2018-09-15       Impact factor: 2.816

3.  Valproic acid mitigates the inflammatory response and prevents acute respiratory distress syndrome in a murine model of Escherichia coli pneumonia at the expense of bacterial clearance.

Authors:  George Kasotakis; Manuel Galvan; Elizabeth King; Beda Sarkar; Arthur Stucchi; Joseph P Mizgerd; Peter A Burke; Daniel Remick
Journal:  J Trauma Acute Care Surg       Date:  2017-04       Impact factor: 3.313

4.  Looking beyond macroventilatory parameters and rethinking ventilator-induced lung injury.

Authors:  Michaela C Kollisch-Singule; Sumeet V Jain; Penny L Andrews; Joshua Satalin; Louis A Gatto; Jesús Villar; Daniel De Backer; Luciano Gattinoni; Gary F Nieman; Nader M Habashi
Journal:  J Appl Physiol (1985)       Date:  2017-11-16

5.  Resolved versus confirmed ARDS after 24 h: insights from the LUNG SAFE study.

Authors:  Fabiana Madotto; Tài Pham; Giacomo Bellani; Lieuwe D Bos; Fabienne D Simonis; Eddy Fan; Antonio Artigas; Laurent Brochard; Marcus J Schultz; John G Laffey
Journal:  Intensive Care Med       Date:  2018-04-09       Impact factor: 17.440

6.  Rapidly Improving ARDS in Therapeutic Randomized Controlled Trials.

Authors:  Edward J Schenck; Clara Oromendia; Lisa K Torres; David A Berlin; Augustine M K Choi; Ilias I Siempos
Journal:  Chest       Date:  2018-10-22       Impact factor: 9.410

7.  On the complexity of scoring acute respiratory distress syndrome: do not forget hemodynamics!

Authors:  Xavier Repessé; Alix Aubry; Antoine Vieillard-Baron
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

8.  Initial synchronized intermittent mandatory ventilation versus assist/control ventilation in treatment of moderate acute respiratory distress syndrome: a prospective randomized controlled trial.

Authors:  Jian Luo; Mao-Yun Wang; Bin-Miao Liang; He Yu; Fa-Ming Jiang; Ting Wang; Chao-Li Shi; Pei-Jun Li; Dan Liu; Xiao-Ling Wu; Zong-An Liang
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

9.  Paediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE): an international, observational study.

Authors:  Robinder G Khemani; Lincoln Smith; Yolanda M Lopez-Fernandez; Jeni Kwok; Rica Morzov; Margaret J Klein; Nadir Yehya; Douglas Willson; Martin C J Kneyber; Jon Lillie; Analia Fernandez; Christopher J L Newth; Philippe Jouvet; Neal J Thomas
Journal:  Lancet Respir Med       Date:  2018-10-22       Impact factor: 30.700

10.  Association Between Peripheral Blood Oxygen Saturation (SpO2)/Fraction of Inspired Oxygen (FiO2) Ratio Time at Risk and Hospital Mortality in Mechanically Ventilated Patients.

Authors:  Jason Y Adams; Angela J Rogers; Alejandro Schuler; Gregory P Marelich; Jennifer M Fresco; Sandra L Taylor; Albert W Riedl; Jennifer M Baker; Gabriel J Escobar; Vincent X Liu
Journal:  Perm J       Date:  2020-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.